| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Murlentamab | 3C23-K; GM-102 | Phase 2 Clinical | Lfb Biotechnologies Sas | Colorectal Neoplasms; Genital Neoplasms, Female | Details |

BettinastraBe 30, 60325 Frankfurt am Main



